Viking Therapeutics (VKTX) COO discloses new equity grants and tax-related share sales

Rhea-AI Filing Summary

Viking Therapeutics reported insider equity activity by its Chief Operating Officer. On January 2, 2026, the officer received 41,000 restricted stock units and an additional 32,049 shares from performance-based restricted stock units, both at $0 cost, increasing beneficial ownership. On the same date, the officer was also granted a stock option for 91,000 shares at an exercise price of $35.42 per share, vesting in equal annual installments over four years. On January 5, 2026, a total of 57,661 shares were automatically sold in multiple transactions at weighted-average prices between about $31.87 and $35.20 to cover tax withholding obligations tied to these vesting awards. Following these transactions, the officer beneficially owned 409,190 shares of Viking Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Marianna

(Last) (First) (Middle)

C/O VIKING THERAPEUTICS, INC.

9920 PACIFIC HEIGHTS BLVD, SUITE 350

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.00001 per share	01/02/2026		A		41,000(1)	A	$0	434,802(2)	D
Common Stock, par value $0.00001 per share	01/02/2026		A		32,049(3)	A	$0	466,851	D
Common Stock, par value $0.00001 per share	01/05/2026		S		31,961(4)	D	$32.2928(5)	434,890	D
Common Stock, par value $0.00001 per share	01/05/2026		S		13,600(4)	D	$33.3732(6)	421,290	D
Common Stock, par value $0.00001 per share	01/05/2026		S		10,500(4)	D	$34.2193(7)	410,790	D
Common Stock, par value $0.00001 per share	01/05/2026		S		1,600(4)	D	$35.0731(8)	409,190	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.42	01/02/2026		A		91,000		(9)	01/02/2036	Common Stock	91,000	$0	91,000	D

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.

2. Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 108 shares acquired on May 20, 2025 and 116 shares acquired on November 20, 2025 both pursuant to the Issuer's 2024 Employee Stock Purchase Plan.

3. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal.

4. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3.

5. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

6. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

7. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

8. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

9. 25% of the shares subject to the option will vest on each anniversary of the grant date.

	/s/ Michael Morneau, as Attorney-in-Fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for Viking Therapeutics (VKTX)?

The Chief Operating Officer of Viking Therapeutics reported multiple equity transactions, including grants of restricted stock units, vesting of performance-based awards, a new stock option grant, and automatic share sales to cover tax withholding obligations.

How many Viking Therapeutics (VKTX) shares did the officer acquire on January 2, 2026?

On January 2, 2026, the officer acquired 41,000 shares through a restricted stock unit award and 32,049 additional shares from performance-based restricted stock unit vesting, all at $0 cost.

What stock option grant was reported for the Viking Therapeutics (VKTX) officer?

The officer received a stock option covering 91,000 shares of Viking Therapeutics common stock with an exercise price of $35.42 per share. According to the disclosure, 25% of the shares under the option vest on each anniversary of the January 2, 2026 grant date.

Why were Viking Therapeutics (VKTX) shares sold on January 5, 2026?

The filing states that shares sold on January 5, 2026 were automatically sold on a non-discretionary basis solely to satisfy tax withholding obligations arising from the vesting of restricted stock unit and performance restricted stock unit awards.

At what prices were the Viking Therapeutics (VKTX) shares sold to cover taxes?

The sales on January 5, 2026 occurred in multiple transactions at weighted-average prices of $32.2928, $33.3732, $34.2193, and $35.0731 per share, with underlying trade price ranges disclosed between $31.87 and $35.20 per share.

How many Viking Therapeutics (VKTX) shares does the officer own after these transactions?

After the reported acquisitions and tax-related sales, the officer beneficially owned 409,190 shares of Viking Therapeutics common stock in direct ownership.

What vesting terms apply to the Viking Therapeutics (VKTX) RSU and option awards?

The 41,000-share RSU award vests one-third on each one-year anniversary of the grant date. The stock option for 91,000 shares vests 25% on each anniversary of the grant date, and the performance RSUs vested based on achievement of specified non-financial performance goals.